logo
  • About
    • The Idea
    • The Concept
    • Strategy
  • Opportunity
    • The Need
    • The Market
    • The Unique Concept
    • The Competition
  • Scientific Foundation
    • Knowledge Platform
    • Modes of Action
    • Results
    • IPR
  • Publications
  • Team
  • News
  • Contact

Approved clinical trial application for BioC gel on complex wounds

19 October, 2022
|In News
|By Helene Hartman

The CTA (Clinical Trial Application) has been approved by the Swedish Medical Products Agency (Läkemedelsverket) and the Ethics committee. The study will include patients with large complex wounds and the aim is to show safety and tolerability.

Recent Posts

  • Xinnate raises SEK 31 million in oversubscribed share issue
  • New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD
  • Xinnate announces successful FDA meeting for TCP-25
  • Xinnate receives Orphan Drug Designation from US FDA for TCP-25
  • Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm

Archives

  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
  • Prev
  • Next
© 2025 Xinnate. All rights reserved